Tucotuzumab celmoleukin

Summary

Tucotuzumab celmoleukin (huKS‑IL2, EMD 273066) is an investigational immunocytokine that couples a humanized anti‑EpCAM monoclonal antibody (KS) with interleukin‑2. It is being explored as a cancer‑directed immune stimulant, administered intravenously, and has been evaluated in pre‑clinical mouse models and early‑phase clinical trials for prostate cancer and extensive‑disease small‑cell lung cancer.

Mechanism of Action

The KS antibody fragment binds EpCAM, a surface antigen over‑expressed on many epithelial tumours. By tethering IL‑2 to the tumour‑bound antibody, the fusion protein concentrates IL‑2 activity at the cancer cell surface, promoting proliferation and activation of NK cells and CD4⁺/CD8⁺ T cells, enhancing antibody‑dependent cellular cytotoxicity and cytokine production. This localized cytokine delivery aims to amplify anti‑tumour immunity while limiting systemic IL‑2 exposure.

What the Research Shows

In a murine colon adenocarcinoma model, combining radiofrequency ablation with intratumoral huKS‑IL2 produced greater tumour growth suppression than either treatment alone, achieving complete tumour resolution in 50 % of mice and generating immunologic memory. A phase‑I trial in androgen‑independent prostate cancer demonstrated that weekly 4‑hour intravenous infusions were generally well tolerated up to 4.3 mg/m², with dose‑limiting toxicities emerging at higher doses; pharmacokinetics showed rapid Cmax and a half‑life of 4–7 h, and immunologic activity was evidenced by increased lymphocytes, NK cells, and ADCC. A phase‑II randomized study in extensive‑disease small‑cell lung cancer used cyclophosphamide followed by tucotuzumab as maintenance; overall, progression‑free and overall survival were comparable to best supportive care, though a non‑significant trend toward longer survival was observed in patients who had prior prophylactic cranial irradiation.

Reported Benefits

Pre‑clinical data suggest tucotuzumab celmoleukin can synergise with local tumour ablation to induce durable tumour regression and immune memory. Early‑phase human studies confirm biologic activity, including lymphocyte and NK‑cell expansion and enhanced ADCC, indicating successful immune stimulation. A subset of small‑cell lung cancer patients receiving prior prophylactic cranial irradiation showed a trend toward longer progression‑free and overall survival, hinting at possible benefit in specific clinical contexts.

Limitations of the Evidence

Clinical efficacy remains unproven; the phase‑II lung‑cancer trial did not demonstrate statistically significant improvements versus supportive care. Evidence is limited to small, non‑randomised cohorts and a single tumour type in mice. Immunogenic antibody responses were detected, and dose‑limiting toxicities limited higher dosing. The observed benefits are confined to pre‑clinical models or exploratory sub‑analyses, requiring larger, controlled studies for confirmation.

Safety Considerations

Tucotuzumab celmoleukin was generally well tolerated at doses up to 4.3 mg/m²; dose‑limiting toxicities (grade ≥ 3) appeared at 2.8 mg/m² and above, including cytokine‑related effects. No hypersensitivity reactions were reported in the phase‑I trial, but anti‑drug antibodies developed after the first cycle. In the lung‑cancer study, adverse events occurred in 92 % of patients receiving the combination versus 48 % with best supportive care, underscoring the need for careful monitoring of immune‑related and hematologic toxicities.

How It Is Administered

The immunocytokine is delivered by intravenous infusion, typically over four hours, once daily for three consecutive days per treatment cycle, with cycles spaced four weeks apart. In pre‑clinical work, intratumoral injection was also employed, but clinical administration has been intravenous only.

Routes of Administration

Goals & Uses

• Ovarian cancer treatmentOncologyModerate
• EpCAM-positive solid tumor treatmentOncologyLow
• Small-cell lung cancer treatmentOncologyLow
• Tumor-targeted IL-2 immunotherapyImmunotherapyModerate

Contraindications

• Severe cardiac diseaseCardiovascularHigh
• Hypersensitivity to IL-2 or anti-EpCAM antibody componentsAllergy/HypersensitivityHigh
• Severe pulmonary dysfunctionPulmonaryHigh
• Active autoimmune diseaseAutoimmunityHigh

Adverse Effects

• Capillary leak syndromeVascularUncommonLeakage of fluid from blood vessels into tissues
• HypotensionCardiovascularUncommonLow blood pressure
• Nausea/vomitingGastrointestinalCommon
• Fever and chillsConstitutionalCommon
• FatigueGeneralCommonLow energy or tiredness
• Infusion-related reactionsHypersensitivityUncommon

Drug Interactions

• CorticosteroidsModerate
• Other immunosuppressantsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative
• Patients with organ transplantsImmunologicalRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; investigated in European clinical trials under development by Merck KGaA.
• United StatesInvestigationalStudied under IND; never approved by FDA. Development largely discontinued.

Never received regulatory approval from FDA, EMA, or other major agencies. Investigated under IND in Phase I/II clinical trials. Development largely discontinued or stalled.

Evidence & Sources

• Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma
  Journal ArticleLowJohnson EE, et al.2009-01-01T00:00:00.000000Z
• Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer
  Journal ArticleModerateGladkov O, et al.2015-01-01T00:00:00.000000Z
• Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer
  Journal ArticleModerateKo YJ, et al.2004-01-01T00:00:00.000000Z

Frequently Asked Questions